Autologous adipose tissue-derived stromal vascular fraction
cells application in patients with osteoarthritis

J 2015

Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis

MICHÁLEK, Jaroslav, Rene MOSTER, Ladislav LUKAC, Kenneth PROEFROCK, Miron PETRASOVIC et. al.

Základní údaje

Originální název

Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis

Autoři

Vydání

Cell Transplantation, Putnam Valley, Cognizant Communication Corporation, 2015, 0963-6897

Další údaje

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.427

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3727/096368915X686760

Klíčová slova anglicky

stromal vascular fraction; cells; adipose tissue; connective tissue; osteoarthritis; therapy

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 7. 2015 16:54, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Stromal vascular fraction (SVF), containing large amount of stem cells and other regenerative cells, can be easily obtained from loose connective tissue that is associated with adipose tissue. Here we evaluated safety and clinical efficacy of freshly isolated autologous SVF cells in a case control study in patients with grade 2-4 degenerative osteoarthritis (OA). A total of 1128 patients underwent standard liposuction under local anesthesia and SVF cells were isolated and prepared for application into 1-4 large joints. A total of 1856 joints, mainly knee and hip joints, were treated with a single dose of SVF cells. 1114 patients were followed for 12.1-54.3 months (median 17.2 months) for safety and efficacy. Modified KOOS/HOOS Clinical Score was used to evaluate clinical effect and was based on pain, non-steroid analgesic usage, limping, extent of joint movement, and stiffness evaluation before and at 3, 6, and 12 months after the treatment. No serious side effects, systemic infection or cancer was associated with SVF cell therapy. Most patients gradually improved 3-12 months after the treatment. At least 75% Score improvement was noticed in 63% of patients and at least 50% Score improvement was documented in 91% of patients 12 months after SVF cell therapy. Obesity and higher grade of OA were associated with slower healing. In conclusion, here we report a novel and promising treatment approach for patients with degenerative OA that is safe, cost-effective, and relying only on autologous cells.

Návaznosti

EE2.3.20.0012, projekt VaV

Název: Mezinárodní konsorcium pro buněčnou terapii a imunoterapii

LM2011017, projekt VaV

Název: Advanced Cell Immunotherapy Unit - ACIU

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Advanced cell immunotherapy unit BVI-ACIU

Citovat

MICHÁLEK, Jaroslav, Rene MOSTER, Ladislav LUKAC, Kenneth PROEFROCK, Miron PETRASOVIC, Jakub RYBAR, Martina CAPKOVA, Ales CHALOUPKA, Adas DARINSKAS, Jaroslav sr. MICHALEK, Jan KŘÍSTEK, Jan TRAVNIK, Petr JABANDŽIEV, Marek CIBULKA, Michal HOLEK, Michal JURÍK, Josef SKOPALÍK, Zlatuše KŘÍSTKOVÁ a Zuzana DUDÁŠOVÁ. Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis. Cell Transplantation. Putnam Valley: Cognizant Communication Corporation, 2015. ISSN 0963-6897. Dostupné z: https://dx.doi.org/10.3727/096368915X686760.

@article{1306734,
   author = {Michálek, Jaroslav and Moster, Rene and Lukac, Ladislav and Proefrock, Kenneth and Petrasovic, Miron and Rybar, Jakub and Capkova, Martina and Chaloupka, Ales and Darinskas, Adas and Michalek, Jaroslav sr. and Křístek, Jan and Travnik, Jan and Jabandžiev, Petr and Cibulka, Marek and Holek, Michal and Jurík, Michal and Skopalík, Josef and Křístková, Zlatuše and Dudášová, Zuzana},
   article_location = {Putnam Valley},
   doi = {http://dx.doi.org/10.3727/096368915X686760},
   keywords = {stromal vascular fraction; cells; adipose tissue; connective tissue; osteoarthritis; therapy},
   issn = {0963-6897},
   journal = {Cell Transplantation},
   title = {Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis},
   url = {http://dx.doi.org/10.3727/096368915X686760},
   year = {2015}
}

TY  - JOUR
ID  - 1306734
AU  - Michálek, Jaroslav - Moster, Rene - Lukac, Ladislav - Proefrock, Kenneth - Petrasovic, Miron - Rybar, Jakub - Capkova, Martina - Chaloupka, Ales - Darinskas, Adas - Michalek, Jaroslav sr. - Křístek, Jan - Travnik, Jan - Jabandžiev, Petr - Cibulka, Marek - Holek, Michal - Jurík, Michal - Skopalík, Josef - Křístková, Zlatuše - Dudášová, Zuzana
PY  - 2015
TI  - Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis
JF  - Cell Transplantation
PB  - Cognizant Communication Corporation
SN  - 09636897
KW  - stromal vascular fraction
KW  - cells
KW  - adipose tissue
KW  - connective tissue
KW  - osteoarthritis
KW  - therapy
UR  - http://dx.doi.org/10.3727/096368915X686760
L2  - http://dx.doi.org/10.3727/096368915X686760
N2  - Stromal vascular fraction (SVF), containing large amount of stem cells and other regenerative cells, can be easily obtained from loose connective tissue that is associated with adipose tissue. Here we evaluated safety and clinical efficacy of freshly isolated autologous SVF cells in a case control study in patients with grade 2-4 degenerative osteoarthritis (OA). A total of 1128 patients underwent standard liposuction under local anesthesia and SVF cells were isolated and prepared for application into 1-4 large joints. A total of 1856 joints, mainly knee and hip joints, were treated with a single dose of SVF cells. 1114 patients were followed for 12.1-54.3 months (median 17.2 months) for safety and efficacy. Modified KOOS/HOOS Clinical Score was used to evaluate clinical effect and was based on pain, non-steroid analgesic usage, limping, extent of joint movement, and stiffness evaluation before and at 3, 6, and 12 months after the treatment. No serious side effects, systemic infection or cancer was associated with SVF cell therapy. Most patients gradually improved 3-12 months after the treatment. At least 75% Score improvement was noticed in 63% of patients and at least 50% Score improvement was documented in 91% of patients 12 months after SVF cell therapy. Obesity and higher grade of OA were associated with slower healing. In conclusion, here we report a novel and promising treatment approach for patients with degenerative OA that is safe, cost-effective, and relying only on autologous cells.
ER  -

MICHÁLEK, Jaroslav, Rene MOSTER, Ladislav LUKAC, Kenneth PROEFROCK, Miron PETRASOVIC, Jakub RYBAR, Martina CAPKOVA, Ales CHALOUPKA, Adas DARINSKAS, Jaroslav sr. MICHALEK, Jan KŘÍSTEK, Jan TRAVNIK, Petr JABANDŽIEV, Marek CIBULKA, Michal HOLEK, Michal JURÍK, Josef SKOPALÍK, Zlatuše KŘÍSTKOVÁ a Zuzana DUDÁŠOVÁ. Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis. \textit{Cell Transplantation}. Putnam Valley: Cognizant Communication Corporation, 2015. ISSN~0963-6897. Dostupné z: https://dx.doi.org/10.3727/096368915X686760.

Podrobný výpis o publikaci